FindMyKOL
Clinical trialNCT07175077RecruitingObservational

7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI)

NCT07175077 is an observational study sponsored by University of Missouri-Columbia. As of 21 Nov 2026, it is recruiting participants. It studies Brain Metastases and Small-cell Lung Cancer. The registry lists an enrollment of 20 participants at 1 site in 1 country. The registry lists a start date of 1 Nov 2025 and a primary completion date of 30 Sept 2027.

SponsorUniversity of Missouri-Columbia →Enrollment20Brain MetastasesSmall-cell Lung Cancer
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT07175077
FieldValue
Registry IDNCT07175077
StatusRecruiting
Study typeObservational study
Lead sponsorUniversity of Missouri-Columbia
Enrollment20
Registered sites1
Countries1
ConditionsBrain Metastases and Small-cell Lung Cancer
Start1 Nov 2025
Primary completion30 Sept 2027
Study completion30 Sept 2027
Last update posted2 Dec 2025

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Comparison of a 7t MRI to standard of care 1.5t/3t MRI scans to determine if earlier detection of brain metastases are possible on a 7t.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Missouri, United States1 site, 1 recruiting
  • University of Missouri

    Columbia

    Bo Lu, MD
    Recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouri: 1 site, 1 recruitingMO1KentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Questions about NCT07175077

Each answer restates registry values shown on this page.

What is NCT07175077?

NCT07175077 is an observational study sponsored by University of Missouri-Columbia. It studies Brain Metastases and Small-cell Lung Cancer.

Is NCT07175077 recruiting?

As of 21 Nov 2026, it is recruiting participants. 1 of its 1 sites list their own status as recruiting.

Who leads NCT07175077?

The registry names Bo Lu, MD (principal investigator, CHAIR & PROFESSOR, DEPARTMENT OF RADIATION ONCOLOGY) as the overall official.

Where does NCT07175077 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

When is NCT07175077 expected to complete?

The registry lists a primary completion date of 30 Sept 2027 and a study completion date of 30 Sept 2027. The sponsor last updated the record on 2 Dec 2025.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.